开云app官网登录入口网页版-官方正版

#晚期NSCLC#

125篇内容 | 2812人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416363, encodeId=e11b141636345, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, objectType=article, longId=735771, objectId=6107e357712b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6107e357712b, replyNumber=0, likeNumber=87, createdTime=2022-08-14, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6107e357712b, moduleTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6107e357712b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416362, encodeId=de9e14163628c, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=【精彩直播】PD-L1高表达晚期NSCLC免疫治疗的选择, objectType=article, longId=733248, objectId=3970e33248b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3970e33248b6, replyNumber=0, likeNumber=70, createdTime=2022-07-27, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3970e33248b6, moduleTitle=【精彩直播】PD-L1高表达晚期NSCLC免疫治疗的选择, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3970e33248b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416361, encodeId=5a92141636172, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=【今晚直播】EGFR经典突变&非经典突变的晚期NSCLC治疗进展, objectType=article, longId=732985, objectId=b7e9e329851b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7e9e329851b, replyNumber=0, likeNumber=84, createdTime=2022-07-23, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7e9e329851b, moduleTitle=【今晚直播】EGFR经典突变&非经典突变的晚期NSCLC治疗进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b7e9e329851b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416359, encodeId=ff08141635930, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Clin Cancer Res：纳武单抗再治疗晚期NSCLC的疗效, objectType=article, longId=728641, objectId=090ae28641b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=090ae28641b6, replyNumber=0, likeNumber=81, createdTime=2022-06-06, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=090ae28641b6, moduleTitle=Clin Cancer Res：纳武单抗再治疗晚期NSCLC的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=090ae28641b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416357, encodeId=f2f9141635e1d, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, objectType=article, longId=727788, objectId=2cfae27788c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cfae27788c8, replyNumber=0, likeNumber=92, createdTime=2022-05-26, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cfae27788c8, moduleTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2cfae27788c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416358, encodeId=2e65141635890, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=65, createdTime=2022-05-25, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416356, encodeId=56ba1416356e3, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, objectType=article, longId=727599, objectId=801de275994a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801de275994a, replyNumber=0, likeNumber=83, createdTime=2022-05-24, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801de275994a, moduleTitle=J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=801de275994a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416360, encodeId=ff28141636030, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, objectType=article, longId=727467, objectId=fe0ae2746739, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe0ae2746739, replyNumber=0, likeNumber=71, createdTime=2022-05-22, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe0ae2746739, moduleTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fe0ae2746739)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416355, encodeId=bbff14163556d, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=75, createdTime=2022-03-28, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416354, encodeId=0d661416354c0, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, objectType=article, longId=300517, objectId=5c7c30051ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c7c30051ed6, replyNumber=0, likeNumber=72, createdTime=2022-03-13, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c7c30051ed6, moduleTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5c7c30051ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416353, encodeId=ef7d1416353ef, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, objectType=article, longId=295378, objectId=2fbf2953e8d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbf2953e8d9, replyNumber=0, likeNumber=87, createdTime=2022-02-11, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbf2953e8d9, moduleTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2fbf2953e8d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416352, encodeId=5ea3141635257, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, objectType=article, longId=295276, objectId=d9be2952e62d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be2952e62d, replyNumber=0, likeNumber=73, createdTime=2022-02-10, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be2952e62d, moduleTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d9be2952e62d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416351, encodeId=76e114163512d, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, objectType=article, longId=294782, objectId=5533294e8241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5533294e8241, replyNumber=0, likeNumber=79, createdTime=2022-01-28, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5533294e8241, moduleTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5533294e8241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416350, encodeId=d9411416350e8, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗, objectType=article, longId=293503, objectId=164d293503c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d293503c3, replyNumber=0, likeNumber=66, createdTime=2022-01-07, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d293503c3, moduleTitle=Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=164d293503c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416349, encodeId=147d141634930, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, objectType=article, longId=292494, objectId=9f45292494ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f45292494ff, replyNumber=0, likeNumber=62, createdTime=2021-12-23, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f45292494ff, moduleTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9f45292494ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416348, encodeId=84a2141634886, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=直播回放：围手术期及局部晚期NSCLC免疫治疗进展, objectType=article, longId=292397, objectId=ddcf29239ee4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddcf29239ee4, replyNumber=0, likeNumber=64, createdTime=2021-12-22, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddcf29239ee4, moduleTitle=直播回放：围手术期及局部晚期NSCLC免疫治疗进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ddcf29239ee4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416347, encodeId=ee81141634ec0, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=免费回看：围手术期及局部晚期NSCLC免疫治疗进展, objectType=article, longId=221669, objectId=1f902216690f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f902216690f, replyNumber=0, likeNumber=70, createdTime=2021-12-09, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f902216690f, moduleTitle=免费回看：围手术期及局部晚期NSCLC免疫治疗进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1f902216690f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416346, encodeId=b05e141634699, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, objectType=article, longId=221301, objectId=e3df221301c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3df221301c8, replyNumber=0, likeNumber=85, createdTime=2021-12-01, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3df221301c8, moduleTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e3df221301c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416345, encodeId=1ccd141634505, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, objectType=article, longId=221184, objectId=7716221184e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7716221184e3, replyNumber=0, likeNumber=68, createdTime=2021-11-29, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7716221184e3, moduleTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7716221184e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416344, encodeId=204e14163449e, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, objectTitle=翟怡：晚期NSCLC抗血管生成与免疫治疗的共赢合作, objectType=article, longId=221083, objectId=aec522108386, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aec522108386, replyNumber=0, likeNumber=67, createdTime=2021-11-27, rootId=0, userName=经常头晕, userId=3b093156350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aec522108386, moduleTitle=翟怡：晚期NSCLC抗血管生成与免疫治疗的共赢合作, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=aec522108386)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

晚期NSCLC

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递

2022-08-14

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

【精彩直播】PD-L1高表达晚期NSCLC免疫治疗的选择

2022-07-27

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

【今晚直播】EGFR经典突变&非经典突变的晚期NSCLC治疗进展

2022-07-23

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Clin Cancer Res：纳武单抗再治疗晚期NSCLC的疗效

2022-06-06

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS

2022-05-26

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2022-05-25

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

J Thorac Oncol: 经治晚期NSCLC使用Atezolizumab单药治疗进展后再联合贝伐珠单抗治疗的疗效

2022-05-24

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效

2022-05-22

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-03-28

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案

2022-03-13

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后

2022-02-11

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效

2022-02-10

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？

2022-01-28

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Thorac Cancer：晚期NSCLC奥希替尼治疗进展后化疗联合免疫治疗优于单纯化疗

2022-01-07

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用

2021-12-23

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

直播回放：围手术期及局部晚期NSCLC免疫治疗进展

2021-12-22

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

免费回看：围手术期及局部晚期NSCLC免疫治疗进展

2021-12-09

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究

2021-12-01

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究

2021-11-29

经常头晕 (审核中...)

前往app查看评论内容

#晚期NSCLC#

翟怡：晚期NSCLC抗血管生成与免疫治疗的共赢合作

2021-11-27

科室
- - 订阅+
  - 更多科室
工具
服务